Monitoring HIV DNA and cellular activation markers in HIV-infected humanized mice under cART

Virol J. 2018 Dec 17;15(1):191. doi: 10.1186/s12985-018-1101-9.

Abstract

Background: The major obstacle to cure of HIV type-1 infection is the presence of the HIV reservoir, hidden from the immune system and insensitive to combined antiretroviral therapy (cART). Eradication approaches have been hindered by the difficulty for accurately monitoring its size in vivo, especially in the lymphoid organs. Humanized mouse models are a valuable tool for systematically assess the efficacy of therapeutic interventions in reducing the HIV reservoir. Nonetheless, persistence of the HIV reservoir over time, in the presence of cART, has yet to be analyzed in this in vivo model.

Findings: We found that the proviral DNA as well as the total DNA were very stable in the spleen and mesenteric lymph node irrespective of the length of cART. Notably, the amount of proviral DNA was very similar in the spleen and lymph node. Furthermore, we observed a correlation between the percentage of splenic human CD4+ T-cells with total HIV DNA, between the number of human CD38 + CD8+ T-cells in the spleen with the amount of integrated HIV DNA, and eventually between the hCD4/hCD8 ratio in the spleen with integrated as well as total HIV DNA implying that the CD8+ T cells influence the size of the HIV reservoir.

Conclusions: Here, we demonstrated the stability of this reservoir in humanized mice irrespective of the length of cART, confirming the relevancy of this model for HIV latency eradication investigations. Notably, we also found correlates between the frequency of CD4+ T-cells, their activation status and viral parameters, which were analogous to the ones in HIV-infected patients. Thus, hu-mice represent a very valuable HIV latency model.

Keywords: Alu-PCR; HIV reservoir size; HIV-1; Humanized mice; cART.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Retroviral Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • CD4-CD8 Ratio
  • CD4-Positive T-Lymphocytes / virology*
  • CD8-Positive T-Lymphocytes / virology*
  • Cell Line
  • DNA, Viral / genetics*
  • Disease Models, Animal
  • HEK293 Cells
  • HIV Infections
  • HIV-1 / genetics*
  • Humans
  • Lymph Nodes / virology*
  • Mice, Inbred NOD
  • Mice, SCID
  • Proviruses / genetics
  • Spleen / virology*
  • Viral Load

Substances

  • Anti-Retroviral Agents
  • DNA, Viral